Welcome to our dedicated page for Zevra Therapeutics SEC filings (Ticker: ZVRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Zevra Therapeutics filings document the regulatory record of a Nasdaq-listed, Delaware commercial-stage rare-disease therapeutics company. Recent Form 8-K reports furnish quarterly financial results and corporate updates, record leadership and principal financial officer changes, and disclose compensatory arrangements and inducement awards tied to executive appointments.
The filing record also includes definitive proxy materials covering board matters, executive compensation and shareholder voting items. Material-event filings describe the completed transfer of Zevra's SDX portfolio, including AZSTARYS and KP1077, under an asset purchase and settlement agreement, while Exchange Act disclosures identify the company's common stock on the Nasdaq Global Select Market.
Zevra Therapeutics director Tamara A. Favorito received a grant of stock options for 30,000 shares of common stock on June 4, 2026. The options have an exercise price of $11.17, matching the Nasdaq closing price on the grant date, and expire on June 3, 2036. All 30,000 shares underlying the options vest 100% on the earlier of the first anniversary of the grant, the day before the first annual stockholders meeting after the grant, or immediately before a change in control, subject to her continued board service. The grant was awarded as compensation under Zevra’s non-employee director compensation policy.
Zevra Therapeutics director Alicia Secor received a grant of stock options to acquire 30,000 shares of common stock as compensation for her board service. The options have an exercise price of $11.17 per share, equal to the June 4, 2026 closing price, vest 100% upon the earliest of specified service-based dates, and expire on June 3, 2036.
Zevra Therapeutics director Corey Michael Watton received a grant of stock options for 30,000 shares of common stock. The options have an exercise price of $11.17 per share, matching the June 4, 2026 Nasdaq closing price, and expire on June 3, 2036.
This award was granted as compensation for his service on the board under Zevra’s non-employee director compensation policy, not through open-market buying. All 30,000 options vest 100% on the earlier of the first anniversary of the grant, the day before the first annual stockholders meeting after the grant, or immediately before a change in control, assuming continued board service.
Zevra Therapeutics director Douglas W. Calder received a grant of stock options as board compensation. The award covers 30,000 options to buy common stock at an exercise price of $11.17 per share, matching the Nasdaq closing price on June 4, 2026.
All 30,000 options vest 100% on the earlier of the first anniversary of grant, the day before the first annual stockholders meeting after the grant date, or immediately before a change in control, subject to continued service. Following this grant, Calder holds 30,000 options directly.
Zevra Therapeutics, Inc. director Thomas Anderson received a grant of stock options covering 30,000 shares of common stock as compensation for his board service. The options have an exercise price of $11.17 per share, matching the Nasdaq closing price on June 4, 2026, and expire on June 3, 2036. All 30,000 options vest 100% on the earlier of the first anniversary of the grant date, the day before the first annual stockholders meeting after the grant, or immediately before a change in control, subject to his continued service.
Zevra Therapeutics director Alvin Shih received a grant of 30,000 stock options to buy common stock at an exercise price equal to the Nasdaq closing price of $11.17 on June 4, 2026. The options vest 100% on the earlier of the first anniversary, the day before the first annual stockholders meeting after grant, or immediately before a change in control, subject to his continued board service, and expire on June 3, 2036.
Zevra Therapeutics, Inc. reported the results of its 2026 annual stockholder meeting held on June 4, 2026. Stockholders elected Douglas W. Calder and Corey Watton as Class II directors to serve until the 2029 annual meeting and ratified Ernst & Young LLP as independent auditor for the year ending December 31, 2026.
Holders of 46,326,616 shares, or 78.37% of the 59,114,850 shares outstanding as of the record date, were represented at the meeting. Stockholders voted in favor of an amendment to declassify the board, but the proposal did not reach the required more-than 66 2/3% of outstanding shares needed for approval, so the classified board structure remains in place.
Zevra Therapeutics senior vice president of finance and corporate controller Timothy J. Sangiovanni received new equity awards. He was granted 20,000 restricted stock units, each representing one share of common stock, and a stock option for 40,000 shares at an exercise price of $11.40 per share. The option vests in four equal annual installments beginning on March 1, 2027, while the restricted stock units vest one third on March 1, 2027 and the remaining two thirds in equal annual installments thereafter, in each case subject to his continued service.
Zevra Therapeutics Chief Legal & Compliance officer Rahsaan Thompson reported an open-market sale of 1,794 shares of common stock at $11.30 per share. After this transaction, he directly holds 48,125 shares. The sale was executed pursuant to a Rule 10b5-1(c) trading plan adopted on 01-08-2026, indicating it was pre-scheduled rather than a discretionary trade.